Form 4: Moderna CFO Reports Stock Transactions

Moderna's Chief Financial Officer, James M. Mock, reported transactions involving restricted stock units and common stock, including shares withheld for tax obligations.

Summary

• James M. Mock, Chief Financial Officer of Moderna, Inc., reported transactions on June 5, 2026.
• These transactions involved the conversion of restricted stock units (RSUs) into common stock and the disposal of common stock.
• Specifically, 11,798 RSUs converted into common stock, with 11,798 shares acquired.
• Additionally, 5,705 shares of common stock were disposed of at a price of $51.59 per share, with these shares being withheld to satisfy tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Mock beneficially owns 65,687 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports standard insider transactions related to equity compensation and tax obligations, without indicating significant positive or negative shifts in beneficial ownership or market sentiment.

Positives

• The CFO's transactions indicate continued engagement with the company's equity, as RSUs convert to common stock.
• The withholding of shares for tax obligations is a standard procedure and suggests the vesting of RSUs, which can be seen as a positive indicator of employee compensation realization.

Negatives

• The disposal of 5,705 shares of common stock, even if for tax purposes, represents a reduction in the CFO's direct beneficial ownership of the company's stock.
• The sale price of $51.59 per share might be viewed negatively if it is significantly below the prevailing market price at the time, though this information is not detailed in the filing.

Risks

• While not explicitly stated as a risk, any significant sale of stock by a high-ranking executive can sometimes be interpreted by the market as a lack of confidence, although in this case, it appears to be for tax withholding.
• The filing does not detail the market price at the time of the transaction, so a precise comparison to assess potential undervaluation or overvaluation of the disposed shares is not possible.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for corporate insiders. The transactions reported by Moderna's CFO are typical for executives managing equity compensation, particularly concerning tax obligations upon vesting of restricted stock units. Such filings are standard practice across the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The disposal of shares for tax purposes is a routine event and is unlikely to have a significant impact on the share price, though any insider selling can be scrutinized.
• Employees: The vesting of RSUs and subsequent tax withholding confirms the company's compensation structure and the realization of value for executives.
• Management: The transactions reflect the standard management of executive compensation packages.

Next Steps

• Continued vesting of remaining restricted stock units in twelve equal quarterly installments after December 5, 2025.
• Potential future transactions by the reporting person as RSUs vest or based on personal financial planning.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Common Stock, Beneficial Ownership, Tax Withholding, Chief Financial Officer, James M. Mock